10.1016/s1470-2045(20)30641-0 - First-line nivolumab plus ipilimumab ...

This document has been corrected

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

10.1016/s1470-2045(20)30641-0

Published Online: 2021-02-?

Journal: The Lancet Oncology•Publisher: Elsevier BV

Authors: Abderrahim Oukessou•Alejo Lingua•Arnaud Scherpereel•Aurelia Alexandru•Bogdan Zurawski•Claudio Martin•David P Carbone•Eduardo Richardet•Enriqueta Felip•Hiroshi Sakai•Jaafar Bennouna•Jinchun Yan•Juliana Menezes•Luis Paz-Ares•Manuel Cobo•Martin Reck•Maurice Pérol•Michael Schenker•Oscar Juan-Vidal•Pamela Salman•Pedro De Marchi•Pierre-Jean Souquet•Shruti Agrawal•Shun Lu•Stephanie Meadows-Shropshire•Thomas John•Tudor-Eliade Ciuleanu

This document has been corrected

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

10.1016/s1470-2045(20)30641-0

Published Online: 2021-02-?

Journal: The Lancet Oncology

NOW

2021-03-01•Erratum

Correction to Lancet Oncol 2021; 22: 198–211

10.1016/s1470-2045(21)00082-6

* information provided by CrossRef

2021-03-01•Erratum

10.1016/s1470-2045(21)00082-6

* information provided by CrossRef

2021-02-?•Published

This document has been corrected

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

10.1016/s1470-2045(20)30641-0

Published Online: 2021-02-?

Journal: The Lancet Oncology•Publisher: Elsevier BV